There maybe many different explanations for the imbalance, but the drug could also accelerate bladder cancer development, I don't think you can exclude it at this point. I think regulators are going to be very careful with bladder cancer risk because of mechanism of action. At minimum, large post marketing studies will be required:
Personally I think it should be approved, and actos should stay on the market because diabetes drugs are going to have some risk. People have to accept some types of risk for these types of drugs - doctors and patients should be aware of the risks and manage the risks themselves.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.